Widespread use of PTFV1 as a screening tool for diastolic dysfunction in hypertensive patients

Oct 13, 2025 by recoveryshake.com 62 views

Relationship between P-Wave Terminal Force V1 (PTFV1) in Electrocardiography 12 Leads with Left Ventricular Diastolic Dysfunction in Hypertension Patients

Introduction

Hypertension is a major risk factor for cardiovascular disease, and its complications can be severe if left untreated. One of the complications of hypertension is the development of hypertensive heart disease, which is characterized by diastolic dysfunction as an initial symptom. Diastolic dysfunction is a condition where the heart's ability to relax and fill with blood during diastole is impaired, leading to an increase in Left Ventricular End-Diastolic Pressure (LVEDP) and enlargement of the left atrium. Early detection of diastolic dysfunction is crucial to prevent further complications and improve patient outcomes.

The Role of P-Wave Terminal Force V1 (PTFV1) in Electrocardiography

P-Wave Terminal Force V1 (PTFV1) is a parameter measured in electrocardiography (ECG) that reflects the duration and amplitude of the P terminal section in Lead V1. This parameter is useful in detecting structural changes in the left atrium, which can be indicative of diastolic dysfunction. PTFV1 has been shown to be a simple and effective screening tool for detecting diastolic dysfunction in hypertensive patients.

Research Methodology

This study was a cross-sectional study conducted from March 2019 to August 2019 at the Outpatient Polyclinic of Adam Malik Hajj Hospital in Medan. Hypertension patients who met the inclusion criteria underwent electrocardiographic examination to obtain PTFV1 values. Additionally, echocardiography examination was performed to assess the degree of diastolic dysfunction and other parameters. The analysis was then carried out to examine the correlation between PTFV1 value and the degree of diastolic dysfunction.

Research Results

The results of the analysis showed a significant difference in the value of PTFV1 among groups with a degree of diastolic dysfunction. For grade I diastolic dysfunction, the value of PTFV1 obtained was 23.8 mm.MS, while Grade II showed the value of 34.1 mm.MS, and Grade III reached 52.1 mm.MS. The statistical test showed the value of P <0.001, which indicates a strong relationship between PTFV1 and the degree of diastolic dysfunction (R = 0.63, P <0.001). The intersection point of PTFV1 was found to be more than 29.8 mm.

Discussion

The results of this study suggest that PTFV1 can function as a simple and effective screening tool to detect the degree of diastolic dysfunction in hypertensive patients. This is particularly important in areas or health facilities that do not have access to Echocardiography tools, which are often a standard tool for assessing heart function. With the ease of obtaining electrocardiographic data, PTFV1 can be a solution to identify cardiovascular problems earlier, allow faster interventions, and prevent disease progression.

The Importance of Early Detection of Diastolic Dysfunction

Early detection of diastolic dysfunction is crucial to prevent further complications and improve patient outcomes. If left untreated, diastolic dysfunction can lead to more serious complications, including heart failure and arrhythmias. Therefore, the use of PTFV1 must be widely considered in various health facilities, especially in the context of prevention and management of hypertensive heart disease.

Conclusion

This study provides new hope for hypertensive patients and provides alternative methods for monitoring their heart health more effectively. With a deeper understanding of the relationship between PTFV1 and diastolic dysfunction, it is expected to improve the quality of care and health results for hypertensive patients throughout Indonesia. The use of PTFV1 as a screening tool for diastolic dysfunction can be a game-changer in the management of hypertensive heart disease, particularly in areas with limited access to Echocardiography tools.

Recommendations

Based on the findings of this study, the following recommendations are made:

Widespread use of PTFV1 as a screening tool for diastolic dysfunction in hypertensive patients.
Further research is needed to validate the results of this study and explore the use of PTFV1 in other populations.
Development of guidelines for the use of PTFV1 in clinical practice.

Limitations

This study has several limitations, including:

Small sample size: The study was conducted on a relatively small sample size, which may limit the generalizability of the results.
Cross-sectional design: The study was conducted using a cross-sectional design, which may not capture the dynamic nature of diastolic dysfunction.
Limited access to Echocardiography tools: The study was conducted in a setting with limited access to Echocardiography tools, which may limit the generalizability of the results.

Future Directions

Future studies should aim to:

Validate the results of this study using larger sample sizes and more diverse populations.
Explore the use of PTFV1 in other populations, including those with different types of heart disease.
Develop guidelines for the use of PTFV1 in clinical practice.

Conclusion

In conclusion, this study provides new hope for hypertensive patients and provides alternative methods for monitoring their heart health more effectively. With a deeper understanding of the relationship between PTFV1 and diastolic dysfunction, it is expected to improve the quality of care and health results for hypertensive patients throughout Indonesia.
Frequently Asked Questions (FAQs) about P-Wave Terminal Force V1 (PTFV1) and Left Ventricular Diastolic Dysfunction

Q: What is P-Wave Terminal Force V1 (PTFV1)?

A: PTFV1 is a parameter measured in electrocardiography (ECG) that reflects the duration and amplitude of the P terminal section in Lead V1. It is a useful indicator of structural changes in the left atrium, which can be indicative of diastolic dysfunction.

Q: What is left ventricular diastolic dysfunction?

A: Left ventricular diastolic dysfunction is a condition where the heart's ability to relax and fill with blood during diastole is impaired. This can lead to an increase in Left Ventricular End-Diastolic Pressure (LVEDP) and enlargement of the left atrium.

Q: What are the symptoms of left ventricular diastolic dysfunction?

A: The symptoms of left ventricular diastolic dysfunction can be subtle and may include:

Shortness of breath
Fatigue
Swelling in the legs and feet
Coughing
Chest pain

Q: How is left ventricular diastolic dysfunction diagnosed?

A: Left ventricular diastolic dysfunction is typically diagnosed using echocardiography, which measures the heart's function and structure. However, PTFV1 can be used as a screening tool to detect diastolic dysfunction in hypertensive patients.

Q: What is the relationship between PTFV1 and left ventricular diastolic dysfunction?

A: The results of this study suggest that PTFV1 is strongly correlated with the degree of diastolic dysfunction. The value of PTFV1 increases as the degree of diastolic dysfunction increases.

Q: Can PTFV1 be used as a screening tool for left ventricular diastolic dysfunction?

A: Yes, PTFV1 can be used as a screening tool for left ventricular diastolic dysfunction in hypertensive patients. This is particularly important in areas or health facilities that do not have access to Echocardiography tools.

Q: What are the benefits of using PTFV1 as a screening tool for left ventricular diastolic dysfunction?

A: The benefits of using PTFV1 as a screening tool for left ventricular diastolic dysfunction include:

Early detection of diastolic dysfunction
Improved patient outcomes
Reduced risk of complications
Increased access to healthcare services

Q: What are the limitations of using PTFV1 as a screening tool for left ventricular diastolic dysfunction?

A: The limitations of using PTFV1 as a screening tool for left ventricular diastolic dysfunction include:

Small sample size
Cross-sectional design
Limited access to Echocardiography tools

Q: What are the future directions for research on PTFV1 and left ventricular diastolic dysfunction?

A: Future studies should aim to:

Validate the results of this study using larger sample sizes and more diverse populations
Explore the use of PTFV1 in other populations, including those with different types of heart disease
Develop guidelines for the use of PTFV1 in clinical practice

Q: What are the implications of this study for clinical practice?

A: The implications of this study for clinical practice include:

Widespread use of PTFV1 as a screening tool for diastolic dysfunction in hypertensive patients
Development of guidelines for the use of PTFV1 in clinical practice
Increased access to healthcare services for patients with diastolic dysfunction

Q: What are the potential applications of PTFV1 in other areas of medicine?

A: The potential applications of PTFV1 in other areas of medicine include:

Detection of other types of heart disease
Monitoring of heart function in patients with other medical conditions
Development of new treatments for heart disease

Q: What are the potential limitations of PTFV1 in other areas of medicine?

A: The potential limitations of PTFV1 in other areas of medicine include:

Limited availability of PTFV1 data
Limited understanding of the relationship between PTFV1 and other medical conditions
Limited access to Echocardiography tools.